Management of the polyallergic patient with allergy immunotherapy: a practice-based approach

Abstract : BackgroundThe great majority (60–80 %) of patients consulting specialist physicians for allergic respiratory disease are polysensitized and thus may be potentially clinically polyallergic. However, management approaches to allergen immunotherapy (AIT) in polysensitized and polyallergic patients are not standardized.MethodsAn international group of clinicians with in-depth expertise in AIT product development, clinical trials and clinical practice met to generate up-to-date, unambiguous, pragmatic guidance on AIT in polysensitized and polyallergic patients. The guidance was developed after reviewing (1) the current stance of regulatory bodies and learned societies, (2) the literature data on single- and multi-AIT and (3) the members’ confirmed clinical experience with polysensitized patients.ResultsAIT is safe and effective in polysensitized and polyallergic patients, and should always be based on the identification of one or more clinically relevant allergens (based on the type and severity of symptoms, the duration of induced symptoms, the impact on quality of life and how difficult an allergen is to avoid). Single-AIT is recommended in polyallergic patients in whom one of the relevant allergens is nevertheless clearly responsible for the most intense and/or bothersome symptoms. Parallel 2-allergen immunotherapy or mixed 2-allergen immunotherapy is indicated in polyallergic patients in whom two causal relevant allergens have a marked clinical and QoL impact. In parallel 2-allergen immunotherapy (whether subcutaneous or sublingual), high-quality, standardized, single-allergen formulations must be administered with an interval of 30 min. Mixing of allergen extracts may be considered, as long as (1) the mixture is technically feasible, (2) the mixture is allowed from a regulatory standpoint, (3) the allergen doses are reduced in proportion to the number of components but are still at concentrations with demonstrated efficacy.ConclusionsPhysicians can prescribe AIT (preferably with high-quality, standardized, single-allergen formulations) with confidence in polysensitized and polyallergic patients by focusing on clinical/QoL relevance and safety.
Type de document :
Article dans une revue
Allergy, Asthma and Clinical Immunology, BioMed Central, 2016, 12 (1), pp.2. 〈10.1186/s13223-015-0109-6〉
Liste complète des métadonnées

Littérature citée [70 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-01254137
Contributeur : Bmc Bmc <>
Soumis le : lundi 11 janvier 2016 - 18:03:14
Dernière modification le : mercredi 21 mars 2018 - 18:57:57
Document(s) archivé(s) le : mardi 12 avril 2016 - 11:39:35

Fichier

13223_2015_Article_109.pdf
Publication financée par une institution

Identifiants

Collections

Citation

Pascal Demoly, Giovanni Passalacqua, Oliver Pfaar, Joaquin Sastre, Ulrich Wahn. Management of the polyallergic patient with allergy immunotherapy: a practice-based approach. Allergy, Asthma and Clinical Immunology, BioMed Central, 2016, 12 (1), pp.2. 〈10.1186/s13223-015-0109-6〉. 〈inserm-01254137〉

Partager

Métriques

Consultations de la notice

378

Téléchargements de fichiers

209